New research reinforces the hypothesis that the gut microbiome triggers mucosal and systemic immune responses in patients with rheumatoid arthritis. The research, published in Arthritis & Rheumatology May 2017, found that subgroups of patients with RA have differential immunoglobulin G (IgG) or IgA immune reactivity with Prevotella copri, an intestinal microbe that appears to be…
A new measurement tool could mean big changes for the treatment of rheumatoid arthritis (RA). With funding from the Rheumatology Research Foundation, Gregg Silverman, MD, led a study that developed a means for the measurement of immunologic memory in autoimmune disease. This new tool will allow rheumatologists and investigators to measure the immunologic defects that…
A systematic review has found that anti-tumor necrosis factor alpha treatment may improve endothelial function in RA patients. Despite the heterogeneity of the included studies, a random-effects model showed a significant improvement in endothelial function in this patient population after receiving infliximab, adalimumab or etanercept…
(Reuters)—The benefits of Johnson and Johnson’s experimental rheumatoid arthritis drug sirukumab do not outweigh the risks, an advisory panel to the U.S. Food and Drug Administration concluded on Wednesday. The panel voted 12-1 that the drug should not be approved, citing safety concerns, including an imbalance in the number of deaths in patients taking sirukumab…
Researchers may have established a relationship between a new RA autoantibody, anti-carbamylated protein (anti-CarP) antibodies, and increased mortality risk. The recent study showed that anti-CarP was the only autoantibody associated with mortality, specifically respiratory system cause of death…
CHICAGO—Sherine E. Gabriel, MD, MSc, professor of medicine at Rutgers Medical School in Newark, N.J., and a past president of the ACR, presented an overview of cardiovascular disease and rheumatology on a Saturday morning to a room overflowing with rheumatologists attending the ACR’s State-of-the-Art Clinical Symposium in April. She noted that physicians have known for a…
Management of rheumatoid arthritis (RA) is complex. The ever-expanding availability of new drugs requires that rheumatologists and patients constantly consider treatment strategies and targets aimed at both disease control and symptom relief while remaining cognizant of the increasing high cost of emerging medications. Given such complexity, guidelines to inform rheumatologists about the most recent developments…
Highlights from the 2017 EULAR Congress MADRID—The anti-IL6 “nanobody,” vobarilizumab, produced mixed results when used with methotrexate (MTX), compared with MTX and placebo, according to results of a 24-week, double-blind Phase 2b study of patients with rheumatoid arthritis (RA), which were presented in an abstract session at the Annual European Congress of Rheumatology (EULAR). The…
A recent study examined the differences in T helper cell subtypes and osteoclast precursors between patients with early RA and healthy controls. Researchers found that standard treatment combined with a single dose of cholecalcipherol may better improve the general health of patients…
NEW YORK (Reuters Health)—In patients with rheumatoid arthritis (RA), disease-activity-guided dose reduction of a tumor necrosis factor inhibitor (TNFi) is safe and effective in the long-term and leads to a large reduction in TNFi use, according to three-year data from the DRESS study. Implementation of this strategy would “vastly improve the cost-effective use of TNFi,” conclude Dr….